Hologic (HOLX) Q3 Revenue Beats 1%

Hologic reported a mixed Q3 FY2025, with GAAP revenue of $1.02 billion and non-GAAP EPS of $1.08 both exceeding analyst expectations and company guidance, primarily driven by strong performance in its Diagnostics and Surgical segments. However, the quarter saw a 10.1% decline in organic Breast Health revenue and a contraction in non-GAAP margins. Looking ahead, significant tariff headwinds from Costa Rica and China are expected to increase inventory costs by $20-25 million per quarter, posing a new challenge despite positive Q4 guidance.

Analysis

Hologic (HOLX) reported mixed results for Q3 FY2025, exceeding analyst consensus with GAAP revenue of $1.02 billion and non-GAAP EPS of $1.08. The top-line beat was driven by a 7.1% increase in Surgical segment sales, aided by the Gynesonics acquisition, and a 64.7% surge in Skeletal Health revenue as the company caught up on unfulfilled orders from prior manufacturing constraints. However, these strengths were offset by significant underlying weakness in the core Breast Health division, which saw a 10.1% organic revenue decline due to a lull in capital equipment replacement. Profitability also faced pressure, with non-GAAP gross and operating margins contracting by 80 and 110 basis points, respectively, attributed to product mix and margin dilution from recent acquisitions. A critical new headwind emerged in the form of tariffs on production from Costa Rica and China, which are expected to increase inventory costs by $20-25 million per quarter, presenting a material risk to future margins. Despite these challenges, management issued optimistic Q4 guidance, forecasting revenue growth of 4.3% to 5.3% and a non-GAAP EPS increase of 7.9% to 10.9%, signaling confidence in a near-term rebound, particularly within the Breast Health segment.

Key Decisions for Investors

• Investors should closely monitor the performance of the Breast Health segment in the upcoming quarter, as the guided rebound from a 10.1% organic decline is critical to validating the company's outlook.
• The primary risk to evaluate is margin compression; scrutinize the company's ability to mitigate the new $20-25 million quarterly tariff impact, which could significantly erode profitability despite guided revenue growth.
• While the strong cash flow and share buybacks are positive, consider the dilutive effect of recent acquisitions on margins against their contribution to revenue growth.
• Given the positive forward guidance, existing holders may maintain their positions, but new capital should be deployed cautiously until there is clear evidence of a recovery in Breast Health and effective management of tariff-related cost pressures.